Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q15477
UPID:
SKI2_HUMAN
Alternative names:
Helicase-like protein
Alternative UPACC:
Q15477; O15005; Q12902; Q15476; Q5ST66
Background:
Superkiller complex protein 2, also known as Helicase-like protein, plays a pivotal role in mRNA decay and quality control. It is a crucial component of the SKI complex, facilitating mRNA extraction from ribosomes and directing it towards degradation. This protein's involvement in ribosome recycling and its association with transcriptionally active genes underscore its significance in cellular processes.
Therapeutic significance:
The protein is linked to Trichohepatoenteric syndrome 2, a condition marked by growth retardation, severe diarrhea, and immunodeficiency. Understanding the role of Superkiller complex protein 2 could open doors to potential therapeutic strategies for this syndrome.